Drugs / Gonal-f® RFF
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GONAL-F | — | 2004-03-25 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01687712 Comparator | Nov 2013 → Sep 2015 | infertility disorder | Fertility Biotech AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gonal-f RFF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687712 ↗ |
| Modality | Protein / enzyme biologic | “Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF)” NCT01687712 ↗ |
| Route | Subcutaneous | “One subcutaneous injection of 225IU Gonal-f® RFF” NCT01687712 ↗ |